Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 August 5, 2025 Commission File Number 001-14978 SMITH & NEPHEW plc (Registrant's name) Building 5, Croxley Park, Hatters Lane, Watford, England, WD18 8YE (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20- ...

Smith & Nephew (SNN) H1 2025 Earnings Call August 05, 2025 03:30 AM ET Company ParticipantsDeepak Nath - CEOJohn Rogers - CFO & Executive DirectorJack Reynolds-Clark - VP - European MedTech Equity ResearchGraham Doyle - Executive Director - Equity ResearchDavid Adlington - Managing DirectorSam England - Director & Head - European Med Tech Equity ResearchVeronika Dubajova - Managing DirectorHassan Al-Wakeel - Director, European MedTech & Services ResearchRobert Davies - Executive DirectorKane Slutzkin - Dire ...

Smith & Nephew (SNN) H1 2025 Earnings Call August 05, 2025 03:30 AM ET Speaker0Welcome to the Smith and Nephew second quarter and first half results meeting. I'm Deepak Nath, I'm the chief executive officer and joining me is chief financial officer John Rogers. So 2025 is a key year of delivery for Smith and Nephew. I'm pleased to announce the results that put us firmly on track for both our full year growth target and the guided step up in profitability. On revenue 6.7% underlying growth in the quarter ref ...

Second Quarter and Half Year 2025 Transformation-driven cash generation enables capital returns *All references are to underlying growth, unless stated otherwise Forward looking statements and non-IFRS measures This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", ...

Core Insights - Smith & Nephew (SNN) is currently rated as a better value opportunity compared to Stryker (SYK) based on various financial metrics and rankings [1][7] Valuation Metrics - SNN has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while SYK has a Zacks Rank of 3 (Hold) [3] - The forward P/E ratio for SNN is 16.03, significantly lower than SYK's forward P/E of 30.22, suggesting SNN is undervalued [5] - SNN's PEG ratio is 0.97, while SYK's PEG ratio is 2.99, further indicating SNN's better value proposition [5] - SNN has a P/B ratio of 2.63 compared to SYK's P/B of 7.36, reinforcing SNN's favorable valuation metrics [6] - These metrics contribute to SNN's Value grade of A and SYK's Value grade of D, highlighting the disparity in their valuation [6]

Core Insights - The article compares two stocks in the Medical - Products sector: Smith & Nephew (SNN) and EssilorLuxottica Unsponsored ADR (ESLOY) to determine which is more attractive to value investors [1] Valuation Metrics - Smith & Nephew has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while EssilorLuxottica has a Zacks Rank of 3 (Hold) [3] - SNN has a forward P/E ratio of 15.83, significantly lower than ESLOY's forward P/E of 35.31, suggesting SNN may be undervalued [5] - The PEG ratio for SNN is 0.96, while ESLOY's PEG ratio is 4.52, indicating SNN's expected earnings growth is more favorable [5] - SNN's P/B ratio is 2.58 compared to ESLOY's P/B of 3.01, further supporting SNN's valuation attractiveness [6] - SNN has a Value grade of A, while ESLOY has a Value grade of D, highlighting SNN's superior valuation metrics [6]

Core Viewpoint - The article highlights the importance of value investing and identifies Smith & Nephew (SNN) as a strong value stock based on various valuation metrics [2][4][7]. Valuation Metrics - Smith & Nephew holds a Zacks Rank of 2 (Buy) and a Value grade of A, indicating strong potential for value investors [4]. - The stock has a P/E ratio of 14.59, significantly lower than the industry average of 21.05, suggesting it may be undervalued [4]. - SNN's Forward P/E has fluctuated between 11.60 and 16.17 over the past year, with a median of 13.91 [4]. - The PEG ratio for SNN is 0.88, compared to the industry average of 2.00, indicating favorable growth expectations relative to its price [5]. - Over the past 52 weeks, SNN's PEG has ranged from 0.67 to 1.47, with a median of 1.12 [5]. - The P/B ratio for SNN is 2.55, which is attractive compared to the industry average of 5.15, further supporting the undervaluation thesis [6]. - SNN's P/B has varied between 1.98 and 2.66 over the past year, with a median of 2.37 [6]. Investment Outlook - The combination of these metrics suggests that Smith & Nephew is likely undervalued, making it a strong candidate for value investors [7].

Core Insights - Smith+Nephew will support select players at The Championships, Wimbledon in 2025, continuing its commitment to showcase its Sports Medicine product portfolio and the purpose of 'Life Unlimited' [1][6] - The company had a successful inaugural sponsorship during Wimbledon 2024, highlighting its brand and technology aimed at aiding athletes in recovery and performance [3] Product Portfolio - The REGENETEN Bioinductive Implant has been used in over 150,000 procedures globally since 2014, showing lower re-tear rates for rotator cuff surgeries compared to conventional methods [4] - The CARTIHEAL AGILI-C Cartilage Repair Implant is the only device approved for treating knee cartilage and osteochondral defects in patients with mild to moderate osteoarthritis, demonstrating significant post-operative improvements [4] - The Q-FIX KNOTLESS All-Suture Anchor offers enhanced fixation strength and aims to set a new benchmark for soft tissue security in joint repair [4] Company Overview - Smith+Nephew, founded in 1856 in Hull, UK, operates in around 100 countries and generated annual sales of $5.8 billion in 2024 [7] - The company focuses on the repair, regeneration, and replacement of soft and hard tissue, with a mission to restore patients' bodies and self-belief through innovative technologies [6]

Core Insights - The article compares Smith & Nephew (SNN) and GE HealthCare Technologies (GEHC) to determine which stock is more attractive to value investors [1] Group 1: Zacks Rank and Earnings Outlook - Smith & Nephew has a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while GE HealthCare Technologies has a Zacks Rank of 5 (Strong Sell) [3] - The improving analyst outlook for SNN suggests a more favorable investment opportunity compared to GEHC [3][7] Group 2: Valuation Metrics - SNN has a forward P/E ratio of 15.21, while GEHC has a forward P/E of 17.91, indicating SNN may be undervalued [5] - The PEG ratio for SNN is 0.92, compared to GEHC's PEG ratio of 2.43, further suggesting SNN's better valuation relative to its expected EPS growth [5] - SNN's P/B ratio is 2.48, while GEHC's P/B ratio is 3.58, reinforcing SNN's position as a more attractive value option [6] Group 3: Value Grades - SNN has a Value grade of A, while GEHC has a Value grade of C, highlighting SNN's stronger valuation metrics [6]